Đang chuẩn bị liên kết để tải về tài liệu:
Chapter 127. Treatment and Prophylaxis of Bacterial Infections (Part 5)

Không đóng trình duyệt đến khi xuất hiện nút TẢI XUỐNG

Vancomycin Clinically important resistance to vancomycin was first described among enterococci in France in 1988. Vancomycin-resistant enterococci (VRE) have subsequently become disseminated worldwide. The genes encoding resistance are carried on plasmids that can transfer themselves from cell to cell and on transposons that can jump from plasmids to chromosomes. Resistance is mediated by enzymes that substitute D-lactate for D-alanine on the peptidoglycan stem peptide so that there is no longer an appropriate target for vancomycin binding. This alteration does not appear to affect cell-wall integrity, however. This type of acquired vancomycin resistance was confined for 14 years to enterococci—more specifically,.

TÀI LIỆU LIÊN QUAN

Chapter 127. Treatment and Prophylaxis of Bacterial Infections (Part 1)

Chapter 127. Treatment and Prophylaxis of Bacterial Infections (Part 2)

Chapter 127. Treatment and Prophylaxis of Bacterial Infections (Part 3)

Chapter 127. Treatment and Prophylaxis of Bacterial Infections (Part 4)

Chapter 127. Treatment and Prophylaxis of Bacterial Infections (Part 5)

Chapter 127. Treatment and Prophylaxis of Bacterial Infections (Part 6)

Chapter 127. Treatment and Prophylaxis of Bacterial Infections (Part 7)

Chapter 127. Treatment and Prophylaxis of Bacterial Infections (Part 8)

Chapter 127. Treatment and Prophylaxis of Bacterial Infections (Part 9)

Chapter 127. Treatment and Prophylaxis of Bacterial Infections (Part 10)

Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.